Resumen de Extreme liver surgery as treatment of liver tumors involving the hepatocaval confluence
Clara Codony Bassols, Santiago López Ben, María Teresa Albiol Quer, Laia Falgueras, Ernesto Castro, A. Codina Barreras, Margarida Casellas, Júlia Gil García, Antoni Codina Cazador, Juan Figueras Felip
Objective Analyze the characteristics, surgical technique, morbidity and survival of patients treated with extreme liver surgery.
Materials and methods We present a series of consecutive patients with malignant liver tumors in hepatocaval confluence treated in a single center with extreme liver surgery (April 2008–March 2015). Data were collected prospectively and analyzed with SPSS 21.0.
Results 12 patients were included. 50 % were male and 50 % were female with a mean age of 59 ± 10 years old. The median of comorbidities was 7 according to the Charlson Age Comorbidity Index. The 75 % of the tumors were metastases, most of them from colorectal cancer. Most of the patients received neoadjuvant chemotherapy and in 58 % preoperative portal embolization was performed. Major hepatectomies were performed (66.7 % extended right hepatectomy, 33.3 % left extended hepatectomy). The 83.3 % of the patients needed vascular reconstruction. Postoperative morbidity was more than grade II in 50 % of the patients according to Dindo–Clavien classification. There was no intraoperative mortality. The postoperative mortality rate at 90 days was 33 % due to hepatic failure and biliary fistula. In December 2015, 33 % of the patients are still alive with a mean survival of 19 months (13–23) with an ECOG Performance Status of 0.
Conclusion Extreme liver surgery carries a high rate of morbidity and mortality that seem to increase with age and with higher tumor volumes, according to the literature. It is a therapeutic option to consider in patients with low comorbidity suffering from malignant neoplasms that involve the hepatocaval confluence, when no other treatment with curative intention can be performed.
